Navigation Links
Vital Therapies Announces Presentation of ELAD(R) 'Artificial Liver' Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
Date:11/6/2007

BOSTON, Nov. 7 /PRNewswire/ -- Vital Therapies, Inc. (VTI), announced today data from two studies of the company's ELAD(R) (Extracorporeal Liver Assist Device) System were presented at the 2007 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, which was held November 2-6 in Boston, Mass.

-- Abstract (#91), "Interim results of Randomized Controlled Trial of

ELAD(R) in Acute on Chronic Liver Disease," was presented in a

parallel session on Monday, November 5th. This controlled, randomized

(2:1) clinical trial enrolled 69 patients with acute-on-chronic liver

failure in two protocols at two centers in Beijing, China. The first

49 patient protocol resulted in a 30 day transplant-free survival rate

of 50% in the controls and 87% in the treated group (p<0.01). The

second protocol, which had a shorter ELAD(R) treatment time, did not

reach statistical significance. Initial conclusions from this trial

demonstrated ELAD(R) is safe and effective in this patient population

when used with the longer treatment time.

-- Abstract (#855), "ELAD(R) Cellular and System Performance

Improvements," was a poster presentation detailing the metabolic

characteristics of the ELAD(R) cartridges in order to optimize

performance.

Terry Winters, Ph.D., Chairman and CEO said, "These data are consistent with our previous research and experience. ELAD is helping patients and the technology continues to be refined for optimum benefit. These are positive developments as we apply for marketing approval in China and advance our U.S. clinical program."

To date, only liver transplantation has been shown to increase survival. However, demand for liver transplantation far exceeds the supply of donor livers, creating a need for an alternative, lifesaving therapy such as ELAD(R). In China alone, an estimated 160 million people suffer from chronic liver infections such as Hepatitis B and C.

About ELAD(R) (Extracorporeal Liver Assist Device)

The ELAD(R) system provides important metabolic support for patients with liver failure, enabling a bridge-to-transplant or recovery, depending on the type and severity of liver disease. The system consists of four cartridges containing cells that function like normal human liver hepatocytes. The cells metabolize toxins and remove waste products while delivering essential proteins into the plasma. These cartridges are incorporated into a blood pumping system at the patient's bedside and enable continuous treatment for up to 12 days. The key to ELAD's(R) performance is a proprietary human hepatocyte cell line that can be grown, stored and shipped worldwide.

About Vital Therapies. Inc.

Vital Therapies, Inc. is a private San Diego-based liver therapy company that was founded in 2003. It is developing the first human liver cell-based system which provides important metabolic support for patients with severe liver failure. The company's manufacturing facility meets cGMP specifications to produce ELAD cartridges for patient treatment.

For more information, please visit VTI's Website at http://www.vitaltherapies.com


'/>"/>
SOURCE Vital Therapies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
2. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
3. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
4. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
5. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/22/2017)... ROCKVILLE, Md. , Sept. 22, 2017  As ... by Republican Senators Bill Cassidy (R-LA) and ... Kalorama Information notes that the medical device industry is ... the medical device tax, the 2.3% excise tax on ... Act.  But they also want covered patients, increased visits ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Leading pediatric oncology ... in Washington, D.C., for the 49th Congress of the International Society of Paediatric ... President of the Center for Cancer and Blood Disorders at Children’s National, ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
Breaking Medicine News(10 mins):